Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -2.50% | -3.47% | +38.30% |
Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Financials (USD)
Sales 2024 * | 2.62M | Sales 2025 * | 9.26M | Capitalization | 132M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -66M | EV / Sales 2024 * | 50.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.3 x |
P/E ratio 2024 * |
-1.96
x | P/E ratio 2025 * |
-2.04
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
Latest transcript on aTyr Pharma, Inc.
1 day | -2.50% | ||
1 week | -3.47% | ||
Current month | +1.56% | ||
1 month | +2.63% | ||
3 months | +32.65% | ||
6 months | +22.64% | ||
Current year | +38.30% |
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John K. Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1.95 | -2.50% | 726,167 |
24-03-27 | 2 | +4.44% | 1,200,945 |
24-03-26 | 1.915 | -0.26% | 282,116 |
24-03-25 | 1.92 | -1.54% | 338,042 |
24-03-22 | 1.95 | -3.47% | 355,219 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.30% | 132M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |